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Summary A panel of doxorubicin-resistant sublines of the human small-cell lung carcinoma cell line GLC4
displays decreasing DNA topoisomerase Ila (TopoIla) mRNA levels with increasing resistance. In the present
study we describe how this decrease may be regulated. No significant differences in TopoIla mRNA stability or
gene arrangement were found, using mRNA slot-blotting and Southern blotting, in the most resistant cell line
compared with the parental cell line. To investigate if Topolla gene copy loss contributed to the mRNA
decrease, fluorescence in situ hybridisation using a TopoIllx-specific probe was performed. During doxorubicin
resistance development, the composition of the population in each cell line shifted with increasing resistance,
from a population in which most cells contain three TopoIla gene copies (GLC4) to a population in which
most cells contain only two copies. A partial revertant of the most resistant cell line displayed a shift back to
the original situation. We conclude that the Topolla gene copy number decrease per cell line is in good
agreement with the decreased TopolIa mRNA and protein levels, and Topoll activity levels in these cell lines
which were described previously.
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Theinterest inDNAtopoisomerases (Topos) hasincreased after
it was found that these essential, DNA conformation-
controlling enzymes are targets for several chemotherapeutic
drugs used in cancer treatment (reviewed by D'Arpa and Liu,
1989). To date one type I DNA topoisomerase (Topol) and two
type II DNA topoisomerases (TopollIx and ,B) have been found
in human cells. Recently Topolla has been the focus of
attention. Although TopolIoc and TopoIIfl display similarities
at the sequence level (Austin et al., 1993), their expression
pattern during the cell cycle is different (Kimura et al., 1994), as
istheirchromosomallocalisation (Tan etal., 1992;Jenkins etal.,
1992)andthedistributionofbothproteinsinthenucleus(Zini et
al., 1994). Furthermore, it was suggested that Topolla is more
sensitive for Topo-targeting drugs than TopoII,B (Drake et al.,
1989)andthatTopolla-mediated strandbreakscontributemost
tocytotoxicity(Woessner etal., 1990). Several reportshavebeen
published correlating Topollcx levels with drug sensitivity
(Davies et al., 1988; Deffie et al., 1989; Fry et al., 1991). One of
the resistance mechanisms of cancer cells to Topoll-targeting
drugs is a reduction ofthe Topoll protein level. This reduction
could be the result ofa number ofchanges at the DNA or RNA
levelin the resistantcells(for recentreviews seeBeck etal., 1993;
Pommier et al., 1994).
In this study we analysed whether changes in the stability
ofTopolIa mRNA, chromosomal rearrangements of the gene
encoding this protein or a decrease in gene copy number per
cell explain the decrease in Topolla mRNA in 2- to 150-fold
doxorubicin (DOX)-resistant small-cell lung carcinoma cell
lines. It was found that the decrease in Topolla mRNA,
observed in the DOX-resistant sublines, could be explained
by selection for a subpopulation containing a decreased
TopoIllI gene copy number.
Materials and methods
Cell lines
The parental human SCLC cell line GLC4 was derived from a
pleural effusion. The DOX-resistant cell line GLC4/ADR,50,x
(the resistance factor to the drug of interest is shown in
subscript) was extensively characterised earlier (Zijlstra et al.,
1987; Meijer et al., 1987, 1991; De Jong et al., 1990, 1991,
1993; Withoff et al., 1994; Versantvoort et al., 1995). Besides
changes on the Topo level other resistance mechanisms such
as expression of the multidrug resistance associated protein
(MRP) (Muller et al., 1994; Versantvoort et al., 1995)
contribute partially to DOX resistance in GLC4/ADR,50x.
GLC4/ADR2, and GLC4/ADR,ox were isolated during in vitro
acquired resistance development against DOX leading to
GLC4/ADR150x. GLC4/ADRprio is a partial revertant of
GLC4/ADR,50X obtained by culturing the latter cell line
without drug for 6 months. Culturing procedures of the
DOX-resistant cell lines were described previously (Versant-
voort et al., 1995). The TopoIlcx mRNA and protein levels
presented in that study and the Topoll activity published by
De Jong et al. (1990) are summarised in Table I. This table
shows that the DOX resistance panel displays a decrease in
mRNA level with increasing resistance. The partial revertant
GLC4/ADRprIO shows an intermediate mRNA level. The
TopoIlcI protein levels follow the mRNA changes. This is
also the case for the Topoll activity. All experiments in the
present study were performed on cell lines which were grown
without drug for 10 to 21 days. All cell lines were cultured in
RPMI-1640 medium (Flow Laboratories, Irvine, UK)
containing 10% fetal calf serum (Gibco, Paisley, UK).
Drugs and restriction enzymes
DOX and actinomycin D were obtained from Farmitalia
Carlo Erba (Milan, Italy) and Boehringer Mannheim
(Almere, The Netherlands) respectively. The restriction
enzymes PstI, BamHI and EcoRI were obtained from USB
(Integro BV, Zaandam, The Netherlands).
Determination of TopoIIoa mRNA stability by mRNA slot-
blotting
A total of 0.5 x 105 log-phase cells ml-' were incubated
continuously with 10 ,ug ml-' actinomycin D to inhibit
transcription and RNA was isolated at t = 0, 0.5, 1, 2, 4
and 8 h using a guanidine isothiocyanate/caesium chloride
method as described earlier (Withoff et al., 1994). The quality
of the RNA samples was checked by agarose gel electro-
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March 1996Table I Results of TopoIIa mRNA slot-blot and Western blotting
experiments and the TopoIl activity assay as published previously
(these levels are expressed as a percentage of the GLC4 value) and
the results of the Topolla gene copy count found by FISH presented
as the number of Topolla copies per 100 cells and as a percentage of
the GLC4 value
No. TopoIIa
TopoIIa TopoIIa TopoII gene copies
mRNA protein activity per 100 cells
%GLC4 %GLC4 %GLC4 %GLC4
Lymphocytes 190
GLC4 100 100 100 287 100
GLC4/ 88a 7la ND 279 97
ADR2x
GLC4/ gga 95' ND 227 80
ADR,ox
GLC4/ 34a 42' 50b 195 68
ADR,5ox
GLC4/ 68a 88' ND 260 90
ADRpriox
aAs described in Versantvoort et al. (1995). bAs described in De Jong
et al. (1990). ND, not determined.
phoresis. Intact RNA (3 ,ug) was transferred onto positively
charged nylon membranes (Hybond N+, Amersham,
Chalfont, UK) using 10 x SSC (1.5 M sodium chloride,
0.15 M sodium citrate, pH 7.0) by slot-blotting for
hybridisation purposes. The c-myc mRNA half-life was
determined using duplicate blots as a reference (Hann et
al., 1984). The experiments were performed in triplicate.
Southern blotting
In order to check for gross genetic rearrangements Southern
blotting was performed with GLC4 and GLC4/ADR150x DNA
restricted with different restriction enzymes (or enzyme
combinations). DNA was isolated by lysing log-phase cells
overnight in a proteinase K buffer [10 mM Tris; pH 7.4,
10 mM EDTA, 150 mM sodium chloride, 0.4% sodium
dodecyl sulphate (SDS)] containing 1 mg ml-' proteinase
K, followed by standard phenol/chloroform extractions and
ethanol precipitations (Sambrook et al., 1989). After
restriction and gel electrophoresis DNA was alkaline
transferred from 1% agarose gels onto positively charged
nylon membranes (Hybond N+) using 0.6 M sodium
chloride/0.4 M sodium hydroxide.
Hybridisation of Southern blots and mRNA slot-blots
The Topollcx probe SPI was kindly provided by KB Tan and
the c-myc probe by RN Eisenman. Probes were labelled with
[32P]dCTP (3000 ci mmol-', Amersham, 's-Hertogenbosch,
The Netherlands) using an oligolabelling kit (Pharmacia
Biotech BV, Woerden, The Netherlands). Blots were
hybridised overnight at 65°C in 0.5 M disodium hydrogen
phosphate, pH 7.2, 1 mM EDTA, 7% SDS. Post-hybridisa-
tion washes were performed in sequentially 2 x SSC/0.1%
SDS, 1 x SCC/0.1% SDS and 0.1 x SSC/0.1% SDS at
65°C for 30 min. Membranes were exposed to Kodak X-
Omat XAR X-ray film (Brunschwig, Amsterdam, The
Netherlands) between intensifying screens at - 80°C. Band
intensities of mRNA slot-blot signals were determined
densitometrically using the UltraScanXL laser densitometer
(Pharmacia, Uppsala, Sweden). Topolloc mRNA expression
levels were corrected for 28S rRNA expression levels
determined after stripping and rehybridisation of the
membranes with a 28S probe.
Probes usedfor FISH
The cosmid clone for Topollac (ICRFc1O5bO4155) was
developed from the Imperial Cancer Research Fund Reference
Library (Lehrach, 1990). It was biotin-labelled using the
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Bionick nick-translation kit (Gibco BRL, Life Technologies,
Paisley, UK). Labelled probe was taken up in hybridisation
solution (50% formamide, 2 x SSC, 500 ig ml-' salmon
sperm DNA, 10% dextran sulphate).
In situ hybridisation
In situ hybridisation was performed essentially as described
before (Nederlof et al., 1992). Metaphase spreads of the cell
lines were fixed in 3:1 methanol, glacial acetic acid for 1 h at
room temperature (RT). Lymphocytes were used as a
control in each hybridisation. Slides were briefly rinsed
with 2 x SSC (1 x SSC is 0.15 M sodium chloride, 0.015 M
sodium citrate, pH 7) and treated with 100 jug ml-' RNAase
A for 1 h at 37°C. Chromosomes were treated with pepsin
(0.01% in 10 mM hydrochloric acid) for 10 min at 37°C.
Pepsin-treated chromosomes were post-fixed for 10 min at
RT in Streck tissue fixative (Streck Laboratories, Omaha,
NE, USA), dehydrated by sequential washings with 70%
ethanol and 100% ethanol, and air dried. Chromosomes
were denatured by heating in 70% formamide, 2 x SSC at
80°C for 3 min and dehydrated. Probes were denatured for
5 min at 80°C and incubated at 37°C for 15 to 30 min
before use, unless stated otherwise by the manufacturer.
Denatured probe (10 pl) was added to the slide and
hybridisation was performed overnight under a sealed
coverslip at 37°C.
Probe detection
Probe detection was performed as described before
(Kallioniemi et al., 1992) with slight modifications. Slides
were washed in 50% formamide, 1 x SSC at 42°C for 20 min,
followed by a wash in 2 x SSC, 42°C, 20 min. All the
following steps were performed at RT. Biotinylated probes
were detected as follows. The first detection layer consisted of
fluorescein isothiocyanate (FITC)-avidin DCS (Vector Labs,
Burlingame, CA, USA) in 4 x SSC-TB [T is 0.05% Tween 20;
B is 0.5% block reagent (Boehringer Mannheim, Lewes,
UK)] for 45 min. Slides were washed for 10 min in 4 x SSC-
T. The second detection layer consisted of biotinylated anti-
avidin D (Vector Labs) in 4 x SSC-TB for 45 min. Again, the
slides were washed for 10 min in 4 x SSC-T. The third
detection layer consisted of FITC-avidin in 4 x SSC-TB for
45 min. The final wash was performed in 4 x SSC-T for
20 min. Slides were dehydrated before mounting in Vecta-
shield H1000 anti-fade medium (Vector Labs) containing
0.3 ig ml-' propidium iodide (PI) and 0.1 HIg ml-' 4,6-
diamino-indole. Fluorescence was detected using the Bio-
Rad MRC-600 laser scanning confocal microscope (Rich-
mond, CA, USA) equipped with a krypton argon laser.
Unedited PI staining and probe signals were stored on optical
disks and have been retained. Images were processed using
edge enhancement algorithms (Comos software, Hemel
Hempstead, Bio-Rad, UK) and stored as separate files. PI
and probe fluorescence signals were merged using Comos and
Nexus software (Bio-Rad). Optimal colour balance of the
pseudocolour images was achieved using image processing
software (Photomagic, Micrografx, TX, USA). Final figures
were annotated in, and directly printed from, Micrografx
Draw, using a dye sublimation printer (Colour Ease, Kodak,
Harrow, UK).
Results
Stability of TopoIIa. mRNA
In Figure 1 the results obtained for GLC4 and GLC4/ADR,50s
are shown. The half-life ofTopolIa mRNA in these cell lines
is longer than 4 h and similar in both cell lines (Figure la).
The small difference in the angle of the best-fitted lines in
Figure la does not indicate that the 66% decrease in Topolla
mRNA is caused by a change in mRNA stability.
Furthermore, it was statistically shown that the two linesxSAA Selection for cells with fewer Topolla gene copies
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did not differ significantly (see legend to Figure 1). As a
control the half-life of c-myc mRNA was determined (Figure
lb). This is approximately 0.5 h which is in agreement with
previous reports (Hann et al., 1984). Again no differences
between cell lines were observed.
Southern blotting
After Southern blotting and hybridisation with the TopoIIla
probe SP1, no evidence for rearrangements was found
(Figure 2). However, using Southern blotting it is not
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Figure 1 Results ofthe stability determination ofTopoI
(a) and c-myc mRNA (b) in GLC4 (-0-) and GLC4/ADRi50n
(- -l- -). The steady state mRNA level at t=0 is expressed at the
100% value. The values presented in this graph are mean results of
three independent experiments. The bars show the standard devi-
ation values. The lines drawn in the graphs are regression lines. The
regression coefficients+standard deviations are: GLC4-TopolIa,
- 10.2+2.2; GLC4/ADRi5ox-TopoIox, - 14.2+2.3; GLC4-c-myc,
-43.8+5.5 and GLC4/ADR15ox-c-myc, -47.6+3.8. The regres-
sion coefficients did not differ significantly (Student's t-test).
21.2 kbp-
5.1 kbp-
2.0 kbp-
possible to quantitate gene copy numbers precisely. There-
fore, we decided to investigate the Topollc gene copy number
per cell in the DOX-resistant cell line panel by FISH.
TopoIIa gene copy number determination using FISH
In Figure 3 representative metaphase spreads hybridised with
the Topollx probe are presented. It shows that GLC4
contains three copies (Figure 3b) while the control
lymphocytes carry two copies (Figure 3a). During the gene
copy studies the heterogeneous character of the cell line
populations was recognised. Subpopulations appeared to be
present within each cell line carrying two or three Topollo
gene copies.
Identification of subpopulations within each cell line
Because the overall decrease in Topollo gene copy number in
the resistant cell lines might be caused by an increase in the
frequency of cells containing decreased gene copy numbers,
each cell line was analysed for the frequency of nuclei
containing one, two, three or four TopoIIcx gene copies per
cell. The results presented in Table II and Figure 3 show that
the parental cell line, GLC4, has a predominant population of
cells containing three TopolIIa gene copies, although a minor
qiihnonilation with two conies is nresent. GLC/ADR..
1 2 resembles the parental cell line. In GLC4/ADR1ox a second
major subpopulation emerges containing two gene copies (see
Figure 3d and e). In GLC4/ADR15ox most cells contain two
lamRNA copies, and only a minor subpopulation contains three
I
Figure 2 Southern blot results obtained after hybridisation with
the Topolla-specific probe SPI. GLC4 (lanes 1 and 3) and GLC4/
ADR150o DNA (lanes 2 and 4) were cut with PstI (lanes I and 2)
or with BamHI and EcoRI (lanes 3 and 4). The same results were
obtained with a second DNA isolation of each cell line. The
position of DNA markers are shown on the left.
Figure 3 Representative metaphase spreads showing Topolla
FISH signals (indicated with arrows) obtained for (a) lympho-
cytes, (b) GLC4, (c) GLC4/ADR2,, (d and e) GLC4/ADR1ox and
(f) GLC4/ADR150o (see text for details).
-Jo
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Table II Description of the various subpopulations present per cell line
TopoIIa gene copy number per cell (frequency)
No. of
One Two Three Four counted
copy copies copies copies metaphases
Lymphocytes 3 (9%) 31 (91%) 0 34
GLC4 1 (2%) 4 (9%) 41 (87%) 1 (2%) 47
GLC4/ADR2, 1 (2%) 9 (14%) 52 (83%) 1 (2%) 63
GLC4/ADR1ox 2 (4%) 36 (64%) 18 (32%) 0 56
GLC4/ADR150o 3 (7%) 38 (88%) 2 (5%) 0 43
GLC4/ADRprI0x 3 (6%) 14 (28%) 33 (66%) 0 50
The results ofcounts ofnuclei containing one, two, three or four Topolla gene copies are presented (frequency between brackets).
copies. Thus, during DOX resistance development in GLC4
cells with a lower TopolIa gene copy number are selected.
GLC4/ADRprI0, which was developed from GLC4/ADR150x,
shows a shift back to the situation in which most cells in the
population contain three TopoIIac copies. From the results in
Table II a percentage of TopolIa present per 100 cells can be
calculated. Table I shows that this number decreases in the
DOX resistance panel with increasing resistance. The lowest
level is reached in GLC4/ADR150x. The partial revertant
shows an intermediate, almost unchanged count. Further-
more, Table I shows that the TopoIIa gene copy number per
100 cells is in agreement with the data obtained by mRNA
slot-blot and Western blotting and with the activity assay.
Thus, a reduction in gene copy number may at least in part
explain the reduced Topollcx in these cell lines.
Discussion
The main reason for Topoll-related drug resistance is a
decreased Topolla enzyme level. There is little information
on how genetic changes contribute to this decrease. In the
DOX-resistant sublines of GLC4 the decrease in TopoIla
protein coincided with decreased mRNA levels. As we have
not found any indication of an altered (mutated) TopoII
being present in GLC4/ADR15ox (De Jong et al., 1993), the
Topolla mRNA decrease may be an important resistance
mechanism, especially in the low resistant cell lines. We
therefore decided to investigate which mechanism caused the
mRNA decrease. Recently, Ritke et al. (1993) described an
etoposide-resistant human leukaemia K562 cell line with a
2.5-fold decreased Topolla mRNA level which was due to a
1.7-fold decrease in the stability of the mRNA. However, in
the most resistant cell line GLC4/ADR150,, no evidence for a
significantly decreased Topollo mRNA stability was found
when compared with GLC4. Both the resistant and the
sensitive cell line have a comparable long half-life (>4 h) for
Topolla mRNA. Ritke et al. (1993) found for K562 Topolla
mRNA a half-life shorter than 2 h. To date Ritke's study and
ours are the only two describing Topolla mRNA stability
data. The half-life of c-myc mRNA in the GLC4 cell lines
(0.5 h) was in agreement with that found in earlier
publications (Hann et al., 1984).
It was shown that genetic alterations on Topolloc gene
level can influence Topolloe protein expression (Coutts et al.,
1993; Keith et al., 1993). The highly resistant cell line GLC4/
ADRI50t did not show rearrangements in the Topollcx gene
using the Southern blot technique. These findings are in
contrast with results obtained by Tan et al. (1989) who
showed that camptothecin- and amsacrine-resistant murine
P388 leukaemia cells contained reduced levels of Topo I and
II activity and mRNA owing to rearrangements of one of the
alleles of the genes encoding TopoI and Topoll respectively.
More recently, Binaschi et al. (1992) described an allelic
rearrangement of the TopollI gene in the relatively
chemoresistant SCLC cell line NCI-H69, which may
contribute to the increased chemoresistance in this cell line.
Our results are in agreement with previous investigations in
the GLC4 model that showed no indications for changed
molecular sizes ofTopollo mRNA (Versantvoort et al., 1995)
or a 'mutated' enzyme activity (De Jong et al., 1993) in
GLC4/ADR150,.
The Southern blot assay is probably not sensitive enough
to preclude the loss of one TopolIcx gene copy in GLC4/
ADR150x precisely. To investigate this option FISH was
performed using a TopolIa-specific probe. With this probe
the majority of the cells in the parental cell line GLC4 were
found to contain three TopollI gene copies and the majority
of the cells present in the GLC4/ADR150, population only
two. The cells with three Topolla gene copies contain an
extra chromosome 17 (as found by chromosome 17 paint,
results not shown). Chromosome 17 changes are often found
in cancer development and gain of additional chromosomal
17 copies may be involved in malignant transformation of
certain tumour types (Tsuji et al., 1994). We did not intend to
study how the additional chromosome 17 copy was gained in
GLC4, but were more interested in the decrease of TopoIlLI
mRNA during resistance development. This decrease is in
contrast with findings obtained for other genes encoding
TopolI drug-handling proteins involved in resistance devel-
opment, which are amplified in drug-resistant tumours and
cell lines such as P-glycoprotein and MRP (Lonn et al., 1994;
Eijdems et al., 1995).
In order to investigate when during resistance develop-
ment this change has taken place we analysed GLC4/ADR2x
and GLC4/ADR1ox, which also display decreased Topolla
mRNA levels. It was found that with increasing DOX
resistance the population composition gradually changes
from a population in which most cells contain three Topolla
gene copies to a population in which most cells contain only
two copies. This change is in agreement with the hypothesis
that during resistance development in human tumours, the
resistant cells are initially sporadically present in a
genetically heterogeneous tumour, and selected by drug
exposure (Dexter and Leith, 1986). In the revertant GLC4/
ADRprI,o the composition of the population shifts back to
the original situation, probably because cells with three
TopolIa gene copies have a growth advantage above cells
with two copies. Recently, it was shown in breast cancer
tumours that the TopoIla gene was co-amplified with the
erbB2 oncogene which is positioned on the same chromo-
some (Keith et al., 1993; Murphy et al., 1995). Thus other
genes on the same chromosome might be essential for the
selection procedure as well.
In Table I it is shown that the percentage Topolla gene
copies per cell line is in agreement with the mRNA and
protein levels. It is not clear whether the small percentage of
GLC4 cells containing two TopoIlac gene copies is a realistic
value as in lymphocytes a small percentage of cells was
found with only one TopolILa gene copy. It is therefore
unclear whether GLC4 cells with two Topolla gene copies
are present initially or the cells with two copies arise during
the exposure to DOX. The fact that Topoll-targeting drugs
can cause genetic alterations was shown in myelodysplasia
and in acute myeloid leukaemia (Pedersen-Bjergaard et al.,
1994). As yet we have no information on the frequency of
the loss of one TopolIa gene copy in other cell lines and
tumours, resistant to DOX or other TopoIla-targetingSelection for cells with fewer Topolla gene copies
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drugs. However, allelic loss has been described for both
Topol and TopoIIa in primary breast cancer biopsies (Keith
et al., 1993).
Another unanswered question is whether transcriptional
down-regulation of TopoIIa mRNA contributes to the down-
regulation of Topollac mRNA in this cell line panel. In
GLC4/ADRl5oX 34% TopoIla mRNA was measured com-
pared with GLC4 (Table I), although the gene copy number
decreases only to 67%. The involvement of transcriptional
regulation was suggested by Husain et al. (1994) for Topol
expression. They presented tumour type-specific differences in
TopoI expression and postulated that increased Topol
mRNA levels may result from increased transcription or
increased mRNA stability.
We do realise that the decrease in TopolIo is not the only
resistance mechanism triggered in this cell line panel [Topoll,
mRNA levels for instance are also decreased in this cell line
panel (Versantvoort et al., 1995)]. In GLC4/ADR2X however,
which may be a better model for resistance development in
the clinical situation with its low resistance factor than highly
resistant cell lines such as GLC4/ADR150,, the Topolla
mRNA decrease may already be an important contribution
to resistance. Therefore, we decided to focus on how the
decrease in Topolla mRNA is caused. In the present study
we show that the decrease in Topolla mRNA level in the
DOX-resistant GLC4 cell line panel is caused by a shift in the
composition of the population in favour of cells containing
fewer than TopolIa gene copies. This decrease results in a
decrease in TopolIa protein expression and thus a decrease in
drug target in the DOX-resistant cell lines.
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